

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

PE anti-human TNF-?

RRID:AB_315261

Type: Antibody

Proper Citation

BioLegend Cat# 502909, RRID:AB_315261

Antibody Information

URL: http://antibodyregistry.org/AB_315261

Proper Citation: BioLegend Cat# 502909, RRID:AB_315261

Target Antigen: TNF-alpha

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: ICFC, FC

Antibody Name: PE anti-human TNF-?

Description: This monoclonal targets TNF-alpha

Target Organism: human

Clone ID: Clone MAb11

Antibody ID: AB_315261

Vendor: BioLegend

Catalog Number: 502909

Alternative Catalog Numbers: 502908

Record Creation Time: 20231110T044954+0000

Record Last Update: 20260829T183452+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human TNF-?.

No alerts have been found for PE anti-human TNF-?.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lee S, et al. (2026) NOT-gated chimeric antigen receptor circuits in T and NK cells. *Cell systems*, 17(4), 101561.

Volpe A, et al. (2026) Membrane-bound TRAIL-arming augments CAR-T cells in mesothelin-positive solid malignancies. *Journal for immunotherapy of cancer*, 14(5).

He S, et al. (2025) Systemic immune activity occurs during human immune system maturation. *Cell*, 188(25), 7291.

Lv J, et al. (2025) Mechanical signaling via $\alpha 2$ integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells. *Immunity*, 58(9), 2289.

Tang M, et al. (2025) Single cell immune profiling in ankylosing spondylitis reveals resistance of CD8⁺ T cells to immune exhaustion. *iScience*, 28(7), 112715.

Zhao Z, et al. (2025) Sickle cell disease induces chromatin introversion and ferroptosis in CD8⁺ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Lin H, et al. (2025) Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. *Cell reports. Medicine*, 6(5), 102117.

Qiu Y, et al. (2025) Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. *Cancer cell*, 43(1), 103.

Zhu M, et al. (2024) Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. *Cell reports*, 43(4), 114065.

Zhang J, et al. (2024) Osr2 functions as a biomechanical checkpoint to aggravate CD8⁺ T cell exhaustion in tumor. *Cell*, 187(13), 3409.

Lin M, et al. (2024) Inflammatory dendritic cells restrain CD11b⁺CD4⁺ CTLs via CD200R in human NSCLC. *Cell reports*, 43(2), 113767.

Huang Y, et al. (2024) Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. *Cell reports. Medicine*, 5(2), 101400.

Thangaraj JL, et al. (2024) Disruption of TGF- β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. *Cell stem cell*, 31(9), 1327.

Ibáñez-Molero S, et al. (2024) Phosphoprotein dynamics of interacting T cells and tumor cells by HySic. *Cell reports*, 43(1), 113598.

Padoan B, et al. (2024) Nkp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells. *Cell reports*, 43(4), 114089.

Si X, et al. (2024) Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. *Cell metabolism*, 36(1), 176.

Song M, et al. (2023) circIFNGR2 regulating ankylosing spondylitis-associated inflammation through macrophage polarization. *iScience*, 26(8), 107325.

West EE, et al. (2023) Loss of CD4⁺ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. *Immunity*, 56(9), 2036.

Cao W, et al. (2023) TRIB2 safeguards naive T cell homeostasis during aging. *Cell reports*, 42(3), 112195.

Hubbard JM, et al. (2022) Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(13), 2818.